Table 1 Relationship between SPP1 and clinicopathological features in 183 PSCC patients
From: SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer
|  | High-SPP1 group (N = 78) | Low-SPP1 group (N = 105) | P-value |
|---|---|---|---|
Age | |||
 < 55 | 44 (56.4%) | 64 (61.0%) | 0.641 |
 > 55 | 34 (43.6%) | 41 (39.0%) | |
pT status | |||
pT1 | 34 (43.6%) | 26 (24.8%) | 0.026 |
pT2 | 12 (15.4%) | 17 (16.2%) | |
pT3 | 25 (33.3%) | 51 (48.6%) | |
pT4 | 6 (7.7%) | 11 (10.5%) | |
pN status | |||
pN0 | 44 (56.4%) | 49 (46.7%) | 0.274 |
pN1 | 9 (11.5%) | 12 (11.4%) | |
pN2 | 11 (14.1%) | 12 (11.4%) | |
pN3 | 14 (17.9%) | 32 (30.5%) | |
Metastasis | |||
M0 | 76 (97.4%) | 99 (94.3%) | 0.506 |
M1 | 2 (2.6%) | 6 (5.7%) | |
Clinical stage | |||
Stage1 | 24 (30.8%) | 22 (21.0%) | 0.215 |
Stage2 | 21 (26.9%) | 24 (22.9%) | |
Stage3 | 16 (20.5%) | 23 (21.9%) | |
Stage4 | 17 (21.8%) | 36 (34.3%) | |
Histology | |||
G1 | 44 (56.4%) | 56 (53.3%) | 0.0369 |
G2 | 29 (37.2%) | 29 (27.6%) | |
G3 | 5 (6.4%) | 20 (19.0%) | |
ENE | |||
Negative | 67 (85.9%) | 79 (75.2%) | 0.112 |
Positive | 11 (14.1%) | 26 (24.8%) | |